Ablative Fractionated Laser Tx Promising for Actinic Keratosis

This article originally appeared here.
Share this content:
Ablative Fractionated Laser Tx Promising for Actinic Keratosis
Ablative Fractionated Laser Tx Promising for Actinic Keratosis

TUESDAY, Feb. 2, 2016 (HealthDay News) -- For patients with actinic keratoses (AKs), one treatment with ablative fractionated laser (AFXL) produces a modest temporary reduction in AKs, according to a study published in the February issue of the Journal of the American Academy of Dermatology.

Stephanie D. Gan, M.D., from the University of Michigan in Ann Arbor, and colleagues examined whether one treatment with AFXL could effectively treat facial AKs. Twelve patients were enrolled into a randomized, controlled, split-face study. Three of the patients were lost to follow-up.

The researchers found that at one month, there were significantly fewer AKs on the treatment side (47 versus 71 percent of baseline lesions); this difference was not sustained at three months (49 versus 57 percent). Most of the AKs that were cleared at one month were thin or grade I (73 versus 36 percent reduction in treated versus untreated; P = 0.002). At the follow-up visits, there was very little change in the number of grade II and III AKs (6 versus 7 percent reduction in treated versus untreated; P = 0.94). After treatment there was a trend toward decreased development of new lesions, although the difference did not reach statistical significance.

"Additional studies with a larger cohort, longer follow-up, and a more diverse patient population are needed to confirm the findings from this preliminary study," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »